

Form PTO-1449 (modified)		Atty. Docket No.: SOBL.P0051US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Kerstin MENANDER Robert E. SOBOL	
		Filing Date: August 11, 2008	Group: 1632
U.S. Patent Documents <i>None</i>	Foreign Patent Documents <i>None</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	"INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy—Introgen, RPR/INGN 201," NCBI Pubmed abstract, PMID: 12749760 of <i>Biodrugs</i> , 17:216-222, 2003.
	C12	Moon <i>et al.</i> , "Current status of gene therapy for lung cancer and head and neck cancer," <i>Clinical Cancer Research</i> , 9: 5055-5067, 2003.
	C13	Office Communication issued in Canadian Patent Application No. 2,557,326, dated May 31, 2011. (SOBL.P0051CA)

90529624.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.